Allo-Glue® Platform

Transformative Small Molecule Glue Discovery & Design

AlloGlues® are small molecule monovalent glues that induce or enhance specific protein-protein interactions by reprogramming protein functions and impacting disease targets through either proximal or distal allosteric mechanisms, including targets once considered “undruggable”. Outcomes of induced proximity include target protein degradation, inhibition, modulation or stabilization. Our fully integrated platform replaces binary and serendipitous discovery with systematic, large-scale discovery, design and optimization of diverse monovalent glues.

Key Features of the Allo-Glue® Platform
The platform integrates multiple technologies that enable molecular interaction complexity to be studied in several dimensions, including:

• Scale and speed in experimental and in-silico data acquisition: large-scale discovery and analysis of protein-protein interactions in living cells by integrating proprietary biological assays with custom automation, robotics, specialized numerical modeling and OrionisBio™ AI/ML tools
• Discovery modes: target-centric, reverse target-centric and ligase-centric approaches enabled at scale
• Chemical diversity: scaffold diversity in our compound libraries enables the exploration of large chemical space
• Specialized Orionis SAR-Enhancer AI: proprietary tools that enable multivariate in-silico interrogation of virtual but readily synthesizable compound space comprising over a trillion molecules – driving rapid SAR and glue optimization cycles
• Protein diversity: empowers interrogation paradigms across ~20,000 proteins (genome-scale) and hundreds of qualified ligases to assess glue-responsive protein interactions in living cells

General drug discovery applications: the platform can support drug discovery and optimization paradigms across virtually any small molecule and target type. This includes genome/proteome-scale assessment of drug-protein interactions.